This laboratory integrates the study of the molecular regulatory mechanisms of hematology under normal physiological conditions with the study of the pathogenesis under disease conditions. It emphasizes the in-depth integration of basic research and clinical transformation, with basic research as the guide and clinical transformation as the ultimate outcome.

1. Research on Hematopoietic Stem Cell Regulation and Blood Cell Regeneration

Focus on the cutting-edge research in hematopoietic stem cell regulation, using multi-omics research methods to construct a molecular network for hematopoietic regulation, clarify the key genes and molecular pathways that affect the expansion and differentiation of hematopoietic stem cells, and screen small molecule compounds that promote the in vitro expansion or directed differentiation of hematopoietic stem cells. Establish an experimental system for the differentiation and regeneration of hematopoietic stem cells into blood cells such as red blood cells in vitro, and develop new blood cell preservation preparations that can extend the preservation period of red blood cells.

2. Research on Novel Strategies for the Treatment of Hematologic Genetic Disorders

Thalassemia remains a severe genetic disease affecting the health of people in Hunan, Guangdong and Guangxi regions. The laboratory will utilize the existing β-thalassemia model mice combined with clinical case samples of thalassemia to screen new therapeutic targets and explore new drugs for thalassemia treatment. The laboratory has already achieved good research foundation in gene therapy for hemophilia and will further study to establish novel treatment methods with clinical application prospects.

3. Research on Novel Diagnostic Biomarkers and Novel Therapeutic Agents for Malignant Hematologic Tumors

Malignant hematologic tumors severely affect human health, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM), etc. Tumor stem cells are closely associated with drug resistance and recurrence of tumors. This platform aims to discover and identify new molecular markers of leukemia stem cells, study new molecules and new pathways related to the occurrence, drug resistance, and recurrence of malignant hematologic tumors, and develop small molecule compounds for the treatment of hematologic tumors, especially targeting tumor stem cells.

4. Establishment, Management and Data Analysis of the Blood Resource Database

By applying the latest generation of life omics technologies such as single-cell sequencing, transcriptomics, metabolomics, and proteomics, and integrating bioinformatics analysis, medical big data mining with the clinical efficacy and prognosis of patients, to establish molecular typing standards and databases for hematopoietic development, hematological tumors, and thalassemia. t also evaluates efficacy-related biomarkers, providing supporting data for the diagnosis, treatment, and prevention of hematologic diseases.